Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide in Adult ETP-ALL
NCT03553238Phase 3Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Feb 2016
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of tucidinostat in Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Event Free Survival at 3 years. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL)
Beyond the preview
Go deeper on NCT03553238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03553238.